Regen Biopharma terminates acquisition negotiations for Canary Oncoceutics stake

Regen BioPharma Inc

Terminated all negotiations to acquire 95% of Canary Oncoceutics.
LOI signed Nov 11, 2021, consideration: $1M cash + stock valued at pre-closing avg price.
As of Feb 18, 2022, no definitive agreement reached; negotiations ended.

item 8.01

Regen BioPharma Inc filing history →

Source: SEC EDGAR

accession 0001607062-22-000137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.